Shares of Health Care sector company Insmed moved -0.3% today, and are now trading at a price of $101.4. The Large-Cap stock's daily volume was 277,241 compared to its average volume of 3,186,480. The S&P 500 index returned a 0.0% performance.
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. The company is based in Bridgewater and has 1,271 full time employees. Its market capitalization is $19,261,032,448.
18 analysts are following Insmed and have set target prices ranging from $90.0 to $125.0 per share. On average, they have given the company a rating of buy. At today's prices, INSM is trading -7.87% away from its average analyst target price of $110.06 per share.
Over the last year, INSM's share price has increased by 51.9%, which represents a difference of 39.4% when compared to the S&P 500. The stock's 52 week high is $106.83 per share whereas its 52 week low is $60.4. Insmed has averaged free cash flows of $-425792166.7 over the last 5 years, with a mean growth rate of -19.2%. It is unlikely that the stock can sustain its current performance trend for the long term when the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | -683,882 | 21,923 | -705,805 | -28.44 |
| 2023 | -536,247 | 13,288 | -549,535 | -33.93 |
| 2022 | -400,439 | 9,878 | -410,317 | -10.72 |
| 2021 | -363,302 | 7,289 | -370,591 | -64.28 |
| 2020 | -219,348 | 6,240 | -225,588 | 22.99 |
| 2019 | -250,649 | 42,268 | -292,917 |
